Evaluation of the effectiveness and adverse events of oxycodone as a pain-relieving agent in 103 dogs with tumors: a retrospective study
Authors:
Open Access
- 2 October 2025
- journal article
- research article
- Published by Springer Nature in BMC Veterinary Research
- Vol. 21 (1) , 1-11
Abstract
Background: Oxycodone, a semi-synthetic opioid, has been widely used in human medicine for the management of tumor-related pain due to its potent analgesic properties. This study aimed to evaluate the efficacy and safety of oxycodone in managing tumor-related pain in dogs, addressing the current lack of research on effective analgesic options for canine cancer dogs. Medical records of 103 tumor-bearing dogs treated with oxycodone were retrospectively reviewed. Results: Oxycodone demonstrated an analgesic effect ranging from 23.1 to 63.6%, depending on the anatomical origin of the tumor. Improvement was observed in 67.7% of dogs with metastatic lesions. In the monotherapy group, the mean pain relief score increased from 8.73 ± 1.27 before treatment to 9.65 ± 1.53 after administration (p < 0.0001). In the combination therapy group, score rose from 8.75 ± 1.20 to 9.83 ± 1.87 (p = 0.0002). Across the entire canine patient cohort, the mean pain relief score increased from 8.74 ± 1.23 to 9.74 ± 1.70 following treatment (p < 0.0001). Adverse effects included lethargy (n = 6), diarrhea (n = 2), vomiting (n = 1), tachypnea (n = 1), and stargazing (n = 1). All were self-limiting and resolved after discontinuation of the drug. Conclusions and clinical importance: Oxycodone demonstrated an overall favorable analgesic profile and could be a well-tolerated and promising pain management solution, both as monotherapy and in combination therapy, for tumor-related pain in dogs, including those with advanced-stage tumors.Keywords
This publication has 53 references indexed in Scilit:
- Relationship between physiological factors and clinical pain in dogs scored using a numerical rating scaleJournal of Small Animal Practice, 1998
- Comparison of Plasma Fentanyl Concentrations by Using Three Transdermal Fentanyl Patch Sizes in DogsVeterinary Surgery, 1998
- The intrinsic antinociceptive effects of oxycodone appear to be κ -opioid receptor mediatedPain, 1997
- Controlled-release oxycodone and morphine in cancer related painPain, 1997
- The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.British Journal of Clinical Pharmacology, 1992
- Morphine and oxycodone hydrochloride in the management of cancer painClinical Pharmacology & Therapeutics, 1990
- Psychomotor, Respiratory and Neuroendocrinological Effects of a μ‐Opioid Receptor Agonist (Oxycodone) in Healthy VolunteersBasic & Clinical Pharmacology & Toxicology, 1989
- The Treatment of Cancer PainNew England Journal of Medicine, 1985
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981
- Determination of Oxycodone in Plasma and Identification of a Major MetaboliteJournal of Pharmaceutical Sciences, 1979